Emerging therapies in thymic epithelial tumors (Review)
- Authors:
- Athina Dapergola
- Georgia Gomatou
- Ioannis Trontzas
- Emmanouil Panagiotou
- Evangelos Dimakakos
- Nikolaos Syrigos
- Elias Kotteas
-
Affiliations: Oncology Unit, Third Department of Medicine, ‘Sotiria’ General Hospital for Diseases of The Chest, National and Kapodistrian University of Athens, Athens 11527, Greece - Published online on: January 16, 2023 https://doi.org/10.3892/ol.2023.13670
- Article Number: 84
-
Copyright: © Dapergola et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Marx A, Chan JKC, Chalabreysse L, Dacic S, Detterbeck F, French CA, Hornick JL, Inagaki H, Jain D, Lazar AJ, et al: The 2021 WHO classification of tumors of the thymus and mediastinum: What is new in thymic epithelial, germ cell, and mesenchymal tumors? J Thorac Oncol. 17:200–213. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Detterbeck FC, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Frazier AA, Giaccone G, Huang J, et al: The IASLC/ITMIG thymic epithelial tumors staging project: Proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol. 9 (9 Suppl 2):S65–S72. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Detterbeck FC, Nicholson AG, Kondo K, Van Schil P and Moran C: The Masaoka-Koga stage classification for thymic malignancies: Clarification and definition of terms. J Thorac Oncol. 6 (7 Suppl 3):S1710–S1716. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Girard N, Ruffini E, Marx A, Faivre-Finn C and Peters S; ESMO Guidelines Committee, : Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26 (Suppl 5):v40–v55. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, et al: NCCN guidelines insights: Non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw. 19:254–266. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Conforti F, Pala L, Giaccone G and De Pas T: Thymic epithelial tumors: From biology to treatment. Cancer Treat Rev. 86:1020142020. View Article : Google Scholar : PubMed/NCBI | |
|
Masaoutis C, Palamaris K, Kokkali S, Levidou G and Theocharis S: Unraveling the immune microenvironment of thymic epithelial tumors: Implications for autoimmunity and treatment. Int J Mol Sci. 23:78642022. View Article : Google Scholar : PubMed/NCBI | |
|
Kondo K, Ohigashi I and Takahama Y: Thymus machinery for T-cell selection. Int Immunol. 31:119–125. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Takaba H and Takayanagi H: The mechanisms of T cell selection in the thymus. Trends Immunol. 38:805–816. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Anderson MS and Su MA: AIRE expands: New roles in immune tolerance and beyond. Nat Rev Immunol. 16:247–258. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Iberg CA, Jones A and Hawiger D: Dendritic cells as inducers of peripheral tolerance. Trends Immunol. 38:793–804. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Owen DL, Sjaastad LE and Farrar MA: Regulatory T cell development in the thymus. J Immunol. 203:2031–2041. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Weksler B and Lu B: Alterations of the immune system in thymic malignancies. J Thorac Oncol. 9 (9 Suppl 2):S137–S142. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Boucher M, Dansin E, Kerjouan M, Mazieres J, Pichon E, Thillays F, Massard G, Quantin X, Youssef O, Westeel V, et al: OA 03.01 prevalence of autoimmune diseases in thymic epithelial tumors (TET) insights from RYTHMIC. J Thorac Oncol. 12 (Suppl 2):S1748–S1749. 2017. View Article : Google Scholar | |
|
Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, et al: The integrated genomic landscape of thymic epithelial tumors. Cancer Cell. 33:244–258.e10. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tateo V, Manuzzi L, De Giglio A, Parisi C, Lamberti G, Campana D and Pantaleo MA: Immunobiology of thymic epithelial tumors: Implications for immunotherapy with immune checkpoint inhibitors. Int J Mol Sci. 21:90562020. View Article : Google Scholar : PubMed/NCBI | |
|
Marchevsky AM and Walts AE: PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus. Hum Pathol. 60:16–23. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Weissferdt A, Fujimoto J, Kalhor N, Rodriguez J, Bassett R, Wistuba II and Moran CA: Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol. 30:826–833. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Owen D, Chu B, Lehman AM, Annamalai L, Yearley JH, Shilo K and Otterson GA: Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma. J Thorac Oncol. 13:1204–1212. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yokoyama S, Miyoshi H, Nishi T, Hashiguchi T, Mitsuoka M, Takamori S, Akagi Y, Kakuma T and Ohshima K: Clinicopathologic and prognostic implications of programmed death ligand 1 expression in thymoma. Ann Thorac Surg. 101:1361–1369. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB and Wakelee HA: Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 10:500–508. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yokoyama S, Miyoshi H, Nakashima K, Shimono J, Hashiguchi T, Mitsuoka M, Takamori S, Akagi Y and Ohshima K: Prognostic value of programmed death ligand 1 and programmed death 1 expression in thymic carcinoma. Clin Cancer Res. 22:4727–4734. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Arbour KC, Naidoo J, Steele KE, Ni A, Moreira AL, Rekhtman N, Robbins PB, Karakunnel J, Rimner A, Huang J, et al: Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. PLoS One. 12:e01826652017. View Article : Google Scholar : PubMed/NCBI | |
|
Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, Manning M, Mogg R, Blumenschein WM, Tan MT, et al: Pembrolizumab in patients with thymic carcinoma: A single-arm, single-centre, phase 2 study. Lancet Oncol. 19:347–355. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Giaccone G and Kim C: Durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up. J Thorac Oncol. 16:483–485. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, Sun JM, Lee SH, Ahn JS, Park K and Ahn MJ: Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial. J Clin Oncol. 37:2162–2170. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Rajan A, Heery CR, Thomas A, Mammen AL, Perry S, O'Sullivan Coyne G, Guha U, Berman A, Szabo E, Madan RA, et al: Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. J Immunother Cancer. 7:2692019. View Article : Google Scholar : PubMed/NCBI | |
|
Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN, Lepone LM, Zekeridou A, Pittock SJ, Hassan R, et al: Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis. 78:150–152. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Katsuya Y, Horinouchi H, Seto T, Umemura S, Hosomi Y, Satouchi M, Nishio M, Kozuki T, Hida T, Sukigara T, et al: Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer. 113:78–86. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ak N and Aydiner A: Nivolumab treatment for metastatic thymic epithelial tumors. J Oncol Pharm Pract. 27:1710–1715. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lattanzio R, La Sorda R, Facciolo F, Sioletic S, Lauriola L, Martucci R, Gallo E, Palmieri G, Evoli A, Alessandrini G, et al: Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: A tissue micro array-based multicenter study. Lung Cancer. 85:191–196. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cimpean AM, Raica M, Encica S, Cornea R and Bocan V: Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat. 190:238–245. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cimpean AM, Ceausu R, Encică S, Gaje PN, Ribatti D and Raica M: Platelet-derived growth factor and platelet-derived growth factor receptor-α expression in the normal human thymus and thymoma. Int J Exp Pathol. 92:340–344. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Janik S, Bekos C, Hacker P, Raunegger T, Schiefer AI, Müllauer L, Veraar C, Dome B, Klepetko W, Ankersmit HJ and Moser B: Follistatin impacts tumor angiogenesis and outcome in thymic epithelial tumors. Sci Rep. 9:173592019. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, Lee S, Ling A, Spittler AJ, Carter CA, et al: Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: An open-label phase 2 trial. Lancet Oncol. 16:177–186. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rajan A, Kim C, Guha U, Szabo E, Berman A, Sciuto L, Spittler AJ, Trepel J, Steinberg S, Harris P, et al: OA18.02 evaluation of a modified dosing regimen (2-weeks on/1-week off) of sunitinib as part of a phase II trial in thymic carcinoma. J Thorac Oncol. 12 (Suppl):S313–S314. 2017. View Article : Google Scholar | |
|
Kim SH, Kim YJ, Ock C, Kim M, Keam B, Kim TM, Kim D, Heo DS and Lee JS: OA11.05 phase II study of sunitinib in patients with thymic carcinoma previously treated with platinum-based chemotherapy (KOSMIC trial). J Thorac Oncol. 13 (Suppl):S346–S347. 2018. View Article : Google Scholar | |
|
Remon J, Girard N, Mazieres J, Dansin E, Pichon E, Greillier L, Dubos C, Lindsay CR and Besse B: Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network. Lung Cancer. 97:99–104. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, et al: Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): A multicentre, phase 2 trial. Lancet Oncol. 21:843–850. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y and Lou L: Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 109:1207–1219. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lin B, Song X, Yang D, Bai D, Yao Y and Lu N: Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene. 654:77–86. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zuo R, Zhang C, Lin L, Meng Z, Wang Y, Su Y, Abudurazik M, Du Y and Chen P: Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review. Thorac Cancer. 11:3383–3387. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yudong S, Zhaoting M, Xinyue W, Li L, Xiaoyan X, Ran Z, Jinliang C and Peng C: EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes. Thorac Cancer. 9:885–891. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Besse B, Girard N, Gazzah A, Hierro C, Tabernero J, Debraud F, Camboni G, Dubois F, Leger C, Legrand F, et al: Clinical activity of lucitanib in advanced thymic epithelial tumours. J Thorac Oncol. 10:S3532015. | |
|
Perrino M, De Pas T, Bozzarelli S, Giordano L, De Vincenzo F, Conforti F, Digiacomo N, Cordua N, D'Antonio F, Borea F, et al: Resound trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy. Cancer. 128:719–726. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Bedano PM, Perkins S, Burns M, Kessler K, Nelson R, Schneider BP, Risley L, Dropcho S and Loehrer PJ: A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol. 26 (15 Suppl):S190872008. View Article : Google Scholar | |
|
Tateo V, Manuzzi L, Parisi C, De Giglio A, Campana D, Pantaleo MA and Lamberti G: An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances. Pharmaceuticals (Basel). 14:3162021. View Article : Google Scholar : PubMed/NCBI | |
|
Girard N, Shen R, Guo T, Zakowski MF, Heguy A, Riely GJ, Huang J, Lau C, Lash AE, Ladanyi M, et al: Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res. 15:6790–6799. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Petrini I, Zucali PA, Lee HS, Pineda MA, Meltzer PS, Walter-Rodriguez B, Roncalli M, Santoro A, Wang Y and Giaccone G: Expression and mutational status of c-kit in thymic epithelial tumors. J Thorac Oncol. 5:1447–1453. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ströbel P, Hartmann M, Jakob A, Mikesch K, Brink I, Dirnhofer S and Marx A: Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med. 350:2625–2626. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H, Niho S, Nagai K and Saijo N: Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer. 62:316–320. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hirai F, Edagawa M, Shimamatsu S, Toyozawa R, Toyokawa G, Nosaki K, Yamaguchi M, Seto T, Twakenoyama M and Ichinose Y: c-kit mutation-positive advanced thymic carcinoma successfully treated as a mediastinal gastrointestinal stromal tumor: A case report. Mol Clin Oncol. 4:527–529. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Buti S, Donini M, Sergio P, Garagnani L, Schirosi L, Passalacqua R and Rossi G: Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. J Clin Oncol. 29:e803–e805. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bisagni G, Rossi G, Cavazza A, Sartori G, Gardini G and Boni C: Long lasting response to the multikinase inhibitor bay 43–9006 (sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol. 4:773–775. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Catania C, Conforti F, Spitaleri G, Barberis M, Preda L, Noberasco C, Lazzari C, Toffalorio F, de Marinis F, Manzotti M and De Pas TM: Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. Onco Targets Ther. 7:697–702. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Dişel U, Oztuzcu S, Beşen AA, Karadeniz C, Köse F, Sümbül AT, Sezer A, Nursal GN, Abalı H and Ozyılkan O: Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer. 71:109–112. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C and Hogendoorn PC: Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol. 4:1270–1273. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Palmieri G, Marino M, Buonerba C, Federico P, Conti S, Milella M, Petillo L, Evoli A, Lalle M, Ceribelli A, et al: Imatinib mesylate in thymic epithelial malignancies. Cancer Chemother Pharmacol. 69:309–315. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pagano M, Sierra NM, Panebianco M, Rossi G, Gnoni R, Bisagni G and Boni C: Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations. Anticancer Res. 34:5105–5110. 2014.PubMed/NCBI | |
|
Neuhaus T and Luyken J: Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma. Target Oncol. 7:247–251. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Li XF, Chen Q, Huang WX and Ye YB: Response to sorafenib in cisplatin-resistant thymic carcinoma: A case report. Med Oncol. 26:157–160. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Schirosi L, Nannini N, Nicoli D, Cavazza A, Valli R, Buti S, Garagnani L, Sartori G, Calabrese F, Marchetti A, et al: Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann Oncol. 23:2409–2414. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Alberobello AT, Wang Y, Beerkens FJ, Conforti F, McCutcheon JN, Rao G, Raffeld M, Liu J, Rahhal R, Zhang YW and Giaccone G: PI3K as a potential therapeutic target in thymic epithelial tumors. J Thorac Oncol. 11:1345–1356. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zucali PA, Petrini I, Lorenzi E, Merino M, Cao L, Di Tommaso L, Lee HS, Incarbone M, Walter BA, Simonelli M, et al: Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer. 116:4686–4695. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Maury JM, Merveilleux du Vignaux C, Drevet G, Zarza V, Chalabreysse L, Maisse C, Gineys B, Dolmazon C, Tronc F, Girard N and Leroux C: Activation of the mTOR/Akt pathway in thymic epithelial cells derived from thymomas. PLoS One. 14:e01976552019. View Article : Google Scholar : PubMed/NCBI | |
|
Zucali PA, De Pas T, Palmieri G, Favaretto A, Chella A, Tiseo M, Caruso M, Simonelli M, Perrino M, De Vincenzo F, et al: Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol. 36:342–349. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hellyer JA, Ouseph MM, Padda SK and Wakelee HA: Everolimus in the treatment of metastatic thymic epithelial tumors. Lung Cancer. 149:97–102. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Padda SK, Gökmen-Polar Y, Hellyer JA, Badve SS, Singh NK, Vasista SM, Basu K, Kumar A and Wakelee HA: Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type. Oncotarget. 12:1178–1186. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Abu Zaid MI, Radovich M, Althouse S, Liu H, Spittler AJ, Solzak J, Badve S and Loehrer PJ Sr: A phase II study of buparlisib in relapsed or refractory thymomas. Front Oncol. 12:8913832022. View Article : Google Scholar : PubMed/NCBI | |
|
Girard N, Teruya-Feldstein J, Payabyab EC, Riely GJ, Rusch VW, Kris MG and Zakowski MF: Insulin-like growth factor-1 receptor expression in thymic malignancies. J Thorac Oncol. 5:1439–1446. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, et al: Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: A multicentre, open-label, phase 2 trial. Lancet Oncol. 15:191–200. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sakane T, Murase T, Okuda K, Saida K, Masaki A, Yamada T, Saito Y, Nakanishi R and Inagaki H: A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3. Histopathology. 75:755–766. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Farina G, Garassino MC, Gambacorta M, La Verde N, Gherardi G and Scanni A: Response of thymoma to cetuximab. Lancet Oncol. 8:449–450. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M and Montella L: Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci. 12:757–761. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kurup A, Burns M, Dropcho S, Pao W and Loehrer PJ: Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol. 23 (16 Suppl):S70682005. View Article : Google Scholar | |
|
Zu Y, Luo Y, Li C, Zhao J, He T, Shi X and Li X: Complete remission following icotinib administration in an advanced ectopic thymic carcinoma patient harbouring the EGFR exon 19 deletion. J Gene Med. 23:e33402021. View Article : Google Scholar : PubMed/NCBI | |
|
Gomatou G, Trontzas I, Ioannou S, Drizou M, Syrigos N and Kotteas E: Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors. Mol Biol Rep. 48:915–925. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Panagiotou E, Gomatou G, Trontzas IP, Syrigos N and Kotteas E: Cyclin-dependent kinase (CDK) inhibitors in solid tumors: A review of clinical trials. Clin Transl Oncol. 24:161–192. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Aesif SW, Aubry MC, Yi ES, Kloft-Nelson SM, Jenkins SM, Spears GM, Greipp PT, Sukov WR and Roden AC: Loss of p16INK4A expression and homozygous CDKN2A deletion are associated with worse outcome and younger age in thymic carcinomas. J Thorac Oncol. 12:860–871. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Besse B, Garassino MC, Rajan A, Novello S, Mazieres J, Weiss GJ, Kocs DM, Barnett JM, Davite C, Crivori P and Giaccone G: Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients. J Clin Oncol. 36 (15 Suppl):S85192018. View Article : Google Scholar | |
|
Ahn MJ, Jung HA, Kim M, Kim JH, Choi YH, Cho J, Park JH, Park KU, Park S, Sun JM, et al: A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor (KCSG LU17-21). J Clin Oncol. 39 (15 Suppl):S85762021. View Article : Google Scholar | |
|
Kirzinger L, Boy S, Marienhagen J, Schuierer G, Neu R, Ried M, Hofmann HS, Wiebe K, Ströbel P, May C, et al: Octreotide LAR and prednisone as neoadjuvant treatment in patients with primary or locally recurrent unresectable thymic tumors: A phase II study. PLoS One. 11:e01682152016. View Article : Google Scholar : PubMed/NCBI | |
|
Palmieri G, Montella L, Martignetti A, Muto P, Di Vizio D, De Chiara A and Lastoria S: Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer. 94:1414–1420. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Loehrer PJ Sr, Wang W, Johnson DH, Aisner SC and Ettinger DS; Eastern Cooperative Oncology Group Phase II Trial, : Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An eastern cooperative oncology group phase II trial. J Clin Oncol. 22:293–299. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Thomas A, Lau C, Rajan A, Zhu Y, Killian JK, Petrini I, Pham T, Morrow B, Zhong X, et al: Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci Rep. 4:73362014. View Article : Google Scholar : PubMed/NCBI | |
|
Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, Trepel J, Lee MJ, Cao L, Espinoza-Delgado I, et al: Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 29:2052–2059. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas A, Rajan A, Szabo E, Tomita Y, Carter CA, Scepura B, Lopez-Chavez A, Lee MJ, Redon CE, Frosch A, et al: A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: A clinical and translational study. Clin Cancer Res. 20:5392–5402. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Conforti F, Zhang X, Rao G, De Pas T, Yonemori Y, Rodriguez JA, McCutcheon JN, Rahhal R, Alberobello AT, Wang Y, et al: Therapeutic effects of XPO1 inhibition in thymic epithelial tumors. Cancer Res. 77:5614–5627. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, Saint-Martin JR, Carlson R, Landesman Y, McCauley D, et al: First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 34:4142–4150. 2016. View Article : Google Scholar : PubMed/NCBI |
